KR101261887B1 - 종양에서 특이적으로 발현되는 유전자 산물 및 이의 용도 - Google Patents

종양에서 특이적으로 발현되는 유전자 산물 및 이의 용도 Download PDF

Info

Publication number
KR101261887B1
KR101261887B1 KR1020047014321A KR20047014321A KR101261887B1 KR 101261887 B1 KR101261887 B1 KR 101261887B1 KR 1020047014321 A KR1020047014321 A KR 1020047014321A KR 20047014321 A KR20047014321 A KR 20047014321A KR 101261887 B1 KR101261887 B1 KR 101261887B1
Authority
KR
South Korea
Prior art keywords
tumor
nucleic acid
leu
ser
associated antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020047014321A
Other languages
English (en)
Korean (ko)
Other versions
KR20040095283A (ko
Inventor
사힌우구르
튀레시외즐렘
코슬로브스키미카엘
Original Assignee
가니메드 파마슈티칼스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가니메드 파마슈티칼스 아게 filed Critical 가니메드 파마슈티칼스 아게
Publication of KR20040095283A publication Critical patent/KR20040095283A/ko
Application granted granted Critical
Publication of KR101261887B1 publication Critical patent/KR101261887B1/ko
Assigned to 비온테크 에스이 reassignment 비온테크 에스이 권리의 전부이전등록 Assignors: 가니메드 파마슈티칼스 게엠베하
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
KR1020047014321A 2002-03-13 2003-03-12 종양에서 특이적으로 발현되는 유전자 산물 및 이의 용도 Expired - Lifetime KR101261887B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10211088.3 2002-03-13
DE10211088A DE10211088A1 (de) 2002-03-13 2002-03-13 Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
PCT/EP2003/002556 WO2003076631A2 (de) 2002-03-13 2003-03-12 Differentiell in tumoren exprimierte genprodukte und deren verwendung

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020117004206A Division KR20110026529A (ko) 2002-03-13 2003-03-12 종양에서 특이적으로 발현되는 유전자 산물 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20040095283A KR20040095283A (ko) 2004-11-12
KR101261887B1 true KR101261887B1 (ko) 2013-11-06

Family

ID=27771250

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020047014321A Expired - Lifetime KR101261887B1 (ko) 2002-03-13 2003-03-12 종양에서 특이적으로 발현되는 유전자 산물 및 이의 용도
KR1020127025908A Ceased KR20120127536A (ko) 2002-03-13 2003-03-12 종양에서 특이적으로 발현되는 유전자 산물 및 이의 용도
KR1020117024468A Abandoned KR20110117735A (ko) 2002-03-13 2003-03-12 종양에서 특이적으로 발현되는 유전자 산물 및 이의 용도
KR1020117004206A Ceased KR20110026529A (ko) 2002-03-13 2003-03-12 종양에서 특이적으로 발현되는 유전자 산물 및 이의 용도

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020127025908A Ceased KR20120127536A (ko) 2002-03-13 2003-03-12 종양에서 특이적으로 발현되는 유전자 산물 및 이의 용도
KR1020117024468A Abandoned KR20110117735A (ko) 2002-03-13 2003-03-12 종양에서 특이적으로 발현되는 유전자 산물 및 이의 용도
KR1020117004206A Ceased KR20110026529A (ko) 2002-03-13 2003-03-12 종양에서 특이적으로 발현되는 유전자 산물 및 이의 용도

Country Status (14)

Country Link
US (8) US7429461B2 (https=)
EP (18) EP2277907A3 (https=)
JP (5) JP4963778B2 (https=)
KR (4) KR101261887B1 (https=)
CN (4) CN103251952B (https=)
AU (2) AU2003219045B2 (https=)
CA (3) CA2478413C (https=)
DE (1) DE10211088A1 (https=)
ES (3) ES2559079T3 (https=)
IL (4) IL163900A0 (https=)
MX (1) MXPA04008867A (https=)
NZ (1) NZ535146A (https=)
PL (1) PL215160B1 (https=)
WO (1) WO2003076631A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP2006514823A (ja) * 2002-08-20 2006-05-18 ミレニアム ファーマスーティカルズ インク 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法
DE10341812A1 (de) * 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2015201738B2 (en) * 2003-09-26 2016-10-13 Biontech Ag Identification of tumour-associated cell surface antigens for diagnosis and therapy
DE10344799A1 (de) * 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004023187A1 (de) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
WO2006073183A1 (ja) * 2005-01-07 2006-07-13 Riken 一塩基多型を用いた炎症性疾患の判定方法
DE102005013846A1 (de) * 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP2862579B1 (en) 2006-10-04 2017-05-17 Dana-Farber Cancer Institute, Inc. Tumor immunity
EP2108701A1 (en) * 2008-04-10 2009-10-14 Ganymed Pharmaceuticals AG Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
CN106103711A (zh) 2013-11-21 2016-11-09 组库创世纪株式会社 T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用
CN105992639B (zh) 2014-03-21 2019-04-16 托普索公司 催化剂支座的免衬垫栅格模块及其模块化系统
HUE052606T2 (hu) * 2014-12-09 2021-05-28 Regeneron Pharma Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
KR20260039788A (ko) 2017-10-10 2026-03-20 시애틀 프로젝트 코포레이션 핫스팟을 이용한 신생항원 동정
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
CN110734925B (zh) * 2018-07-20 2023-04-07 上海市免疫学研究所 一种粒细胞或单核细胞标记系统及其标记方法和应用
US20210214782A1 (en) * 2020-01-09 2021-07-15 Deka Biosciences, Inc. Method of using genetic markers, single nucleotide polymorphisms and/or indels to determine responsiveness to il-10 or il-10 derivative treatment
WO2024002537A1 (en) 2022-06-30 2024-01-04 Kmc Kartoffelmelcentralen Amba Starch based gelatine replacement products

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0270056A1 (en) * 1986-12-01 1988-06-08 Northwestern University Human LDH-C 4cDNA sequences encoding antigenic regions
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
AU1705397A (en) * 1996-01-16 1997-08-11 Northwestern University Proteins and peptides for contraceptive vaccines and fertility diagnosis
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
JP2002503465A (ja) * 1998-02-12 2002-02-05 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒト受容体タンパク質
CA2328128A1 (en) * 1998-05-21 1999-11-25 Diadexus Llc A novel method of diagnosing, monitoring, and staging colon cancer
US6440663B1 (en) * 1998-10-05 2002-08-27 Ludwig Institute For Cancer Research Renal cancer associated antigens and uses therefor
AU6180800A (en) 1999-07-29 2001-02-19 Chugai Research Institute For Molecular Medicine, Inc. Novel gene participating in the maintenance of smooth muscle cell differentiation
AU6181000A (en) * 1999-07-29 2001-02-19 Chugai Research Institute For Molecular Medicine, Inc. Novel genes encoding protein kinase/protein phosphatase
DE19936563A1 (de) * 1999-08-04 2001-02-08 Boehringer Ingelheim Int Tumorassoziiertes Antigen
CA2384713A1 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US7442776B2 (en) 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
WO2001051628A2 (en) * 2000-01-14 2001-07-19 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2001057252A2 (en) * 2000-02-04 2001-08-09 Aeomica, Inc. Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
AU6802801A (en) * 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2002010363A2 (en) * 2000-07-28 2002-02-07 Incyte Genomics, Inc. Protein phosphatases
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
AU2002253878A1 (en) * 2001-01-25 2002-08-06 Gene Logic, Inc. Gene expression profiles in breast tissue
AU2002303219A1 (en) 2001-03-30 2002-10-15 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
US20040058341A1 (en) * 2001-07-26 2004-03-25 Y.Tom Tang Protein phosphatases
EP1487877B1 (en) 2001-09-18 2010-10-27 Genentech, Inc. Compositions and methods for the diagnosis of tumors
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP5565375B2 (ja) 2011-05-12 2014-08-06 三菱電機株式会社 入退室管理装置

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Oncogene, Vol.19, Pages 6550-6565 (2000. 공개) *
Oncogene, Vol.19, Pages 6550-6565 (2000. 공개)*

Also Published As

Publication number Publication date
EP2277905A2 (de) 2011-01-26
EP2277901A3 (de) 2011-05-25
DE10211088A1 (de) 2003-09-25
JP2013055938A (ja) 2013-03-28
IL235085A (en) 2016-06-30
JP5756073B2 (ja) 2015-07-29
AU2008258158A1 (en) 2009-01-15
EP2277903A2 (de) 2011-01-26
EP2314611A2 (de) 2011-04-27
WO2003076631A3 (de) 2004-06-24
EP2277907A3 (de) 2011-05-25
PL373384A1 (en) 2005-08-22
EP2277904A3 (de) 2011-06-08
EP2311862A2 (de) 2011-04-20
US20120014948A1 (en) 2012-01-19
US20090081214A1 (en) 2009-03-26
JP2010047597A (ja) 2010-03-04
CA2813780C (en) 2019-05-07
EP2287181A3 (de) 2011-06-15
US20060013817A1 (en) 2006-01-19
EP2311860B1 (de) 2016-09-07
EP2314611A3 (de) 2011-07-20
CN1646692B (zh) 2015-12-16
CN103251952A (zh) 2013-08-21
EP2311862A3 (de) 2011-07-13
EP2277906A2 (de) 2011-01-26
US20170101479A1 (en) 2017-04-13
IL244596A0 (en) 2016-04-21
EP2311861A2 (de) 2011-04-20
KR20040095283A (ko) 2004-11-12
KR20110117735A (ko) 2011-10-27
US9637794B2 (en) 2017-05-02
CA3035543C (en) 2025-09-23
JP2013172716A (ja) 2013-09-05
ES2688186T3 (es) 2018-10-31
EP2314610A3 (de) 2011-07-20
EP2289910A2 (de) 2011-03-02
EP2277902A2 (de) 2011-01-26
CA2478413C (en) 2020-03-10
AU2008258158A8 (en) 2009-01-29
AU2003219045B2 (en) 2008-09-18
EP2311860A2 (de) 2011-04-20
WO2003076631A2 (de) 2003-09-18
CN103251952B (zh) 2018-11-09
CN1646692A (zh) 2005-07-27
US20150031025A1 (en) 2015-01-29
EP2277907A2 (de) 2011-01-26
CA3035543A1 (en) 2003-09-18
US20160002738A1 (en) 2016-01-07
EP2277904A2 (de) 2011-01-26
EP2287182A2 (de) 2011-02-23
EP2277902A3 (de) 2011-05-25
PL215160B1 (pl) 2013-10-31
KR20120127536A (ko) 2012-11-21
EP2277903A3 (de) 2011-05-25
EP2289910B1 (de) 2018-08-08
EP2314610A2 (de) 2011-04-27
JP2013081462A (ja) 2013-05-09
CA2478413A1 (en) 2003-09-18
EP2287181A2 (de) 2011-02-23
EP2332973A3 (de) 2011-09-07
US8551490B2 (en) 2013-10-08
EP2287182A3 (de) 2011-06-15
IL163900A (en) 2015-07-30
KR20110026529A (ko) 2011-03-15
ES2685053T3 (es) 2018-10-05
IL163900A0 (en) 2005-12-18
AU2003219045A1 (en) 2003-09-22
CN105396144A (zh) 2016-03-16
JP4963778B2 (ja) 2012-06-27
US7429461B2 (en) 2008-09-30
JP5711711B2 (ja) 2015-05-07
EP2314612A3 (de) 2011-08-03
JP5793158B2 (ja) 2015-10-14
EP2311860A3 (de) 2011-07-20
EP2277906A3 (de) 2011-05-25
EP2332973A2 (de) 2011-06-15
EP2314610B1 (de) 2015-08-26
EP1483389B1 (de) 2015-11-04
US8716455B2 (en) 2014-05-06
ES2559079T3 (es) 2016-02-10
US20130243796A1 (en) 2013-09-19
EP1483389A2 (de) 2004-12-08
CA2813780A1 (en) 2003-09-18
NZ535146A (en) 2006-06-30
EP2277901A2 (de) 2011-01-26
EP2311861A3 (de) 2011-07-13
US20090081215A1 (en) 2009-03-26
CN105396144B (zh) 2019-08-20
US9453260B2 (en) 2016-09-27
EP2287182B1 (de) 2018-08-29
EP2314612A2 (de) 2011-04-27
MXPA04008867A (es) 2005-06-17
JP2005519608A (ja) 2005-07-07
EP2277905A3 (de) 2011-05-25
EP2289910A3 (de) 2011-06-15

Similar Documents

Publication Publication Date Title
KR101261887B1 (ko) 종양에서 특이적으로 발현되는 유전자 산물 및 이의 용도
AU2012216265B2 (en) Genetic products differentially expressed in tumors and use thereof
HK1165479A (en) In tumours differentially expressed gene products and use of the same
HK1165464A (en) In tumours differentially expressed gene products and use of the same
HK1165471A (en) In tumours differentially expressed gene products and use of the same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040911

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080312

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100218

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20101022

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100218

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20110124

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20101022

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20130325

Appeal identifier: 2011101000516

Request date: 20110124

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20110223

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20110223

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20110124

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20100719

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20080312

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110408

Patent event code: PE09021S01D

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20110124

Effective date: 20130325

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20130325

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20110124

Decision date: 20130325

Appeal identifier: 2011101000516

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20130408

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20130326

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20130501

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20130502

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20160406

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20160406

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20170426

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20170426

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20180412

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20180412

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20190425

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20190425

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20200428

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20210422

Start annual number: 9

End annual number: 9

PC1801 Expiration of term

Termination date: 20230912

Termination category: Expiration of duration